In the case of Amgen Inc. v. Sandoz Inc., the dispute centres around Otezla® (Apremilast), a formulation extensively used in pharmaceutical industry. Defined within case numbers 2022-1147, 2022-1149, 2022-1150, 2022-1151, and 2023 WL 2994166 (Fed. Cir. Apr. 19, 2023), the proceedings are overseen by Circuit Judges Lourie, Cunningham, and Stark with Justice Lourie giving the opinion on behalf of the court. Notably, the appeal originates from the district court of New Jersey, led by Judge Shipp.
This case brings to light significant questions around pharmaceutical patents, their impact and interpretation. While comprehensive details related to the case are not presently available, one can anticipate the decision will provide meaningful guidance for corporations and legal professionals navigating the complex landscape of pharmaceutical patent law.
Robins Kaplan LLP, a notable law firm with a vast experience in intellectual Property litigation, provide their expert commentary on the unfolding legal proceedings. Therefore, legal professionals with vested interests in complex patent litigation cases, particularly related to pharmaceuticals, will find value in tracking the progress of this case closely.